what are the risks of glp 1 drugs GLP-1 medications linked to major drop in pancreatic, colorectal cancer risk https://www.medicalnewstoday.com/articles/weight-loss-drugs-glp-1-slash-risk -4-types-cancer-50-or-more-study Part 2 of a 3-Part
Description
10.1054/npep.1999.0017 76
Sitagliptin: anti-platelet effect in diabetes and healthy volunteers
A trial of sugar-free or sugar-sweetened beverages and body weight in children
Safety and Clinical Management Safety trials of GLP-1 RAs, including liraglutide, tirzepatide, and semaglutide (oral or subcutaneous), indicate that the most common adverse events (AEs) of treatment are mild to moderate gastrointestinal including nausea, vomiting, diarrhea, constipation, dyspepsia, and decreased appetite
16 The interplay between both SNAC and semaglutide is also essential for absorption
